Ameriprise’s Madrigal Pharmaceuticals MDGL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $51.4M | Buy |
98,181
+68,894
| +235% | +$32.9M | 0.01% | 857 |
|
|
2025
Q4 | $17.1M | Buy |
29,287
+16,290
| +125% | +$8.32M | ﹤0.01% | 1530 |
|
|
2025
Q3 | $5.96M | Buy |
12,997
+4,591
| +55% | +$1.71M | ﹤0.01% | 2306 |
|
|
2025
Q2 | $2.54M | Buy |
8,406
+3,412
| +68% | +$1.02M | ﹤0.01% | 2812 |
|
|
2025
Q1 | $1.65M | Sell |
4,994
-3,674
| -42% | -$1.21M | ﹤0.01% | 2994 |
|
|
2024
Q4 | $2.67M | Sell |
8,668
-28,992
| -77% | -$8.15M | ﹤0.01% | 2758 |
|
|
2024
Q3 | $7.99M | Buy |
37,660
+36,149
| +2,392% | +$9.25M | ﹤0.01% | 1998 |
|
|
2024
Q2 | $423K | Sell |
1,511
-102
| -6% | -$24.3K | ﹤0.01% | 3472 |
|
|
2024
Q1 | $431K | Sell |
1,613
-3,466
| -68% | -$817K | ﹤0.01% | 3465 |
|
|
2023
Q4 | $1.18M | Buy |
5,079
+16
| +0.3% | +$2.8K | ﹤0.01% | 3122 |
|
|
2023
Q3 | $739K | Sell |
5,063
-1,654
| -25% | -$311K | ﹤0.01% | 3266 |
|
|
2023
Q2 | $1.55M | Buy |
6,717
+5,406
| +412% | +$1.46M | ﹤0.01% | 2994 |
|
|
2023
Q1 | $318K | Sell |
1,311
-120
| -8% | -$32.7K | ﹤0.01% | 3597 |
|
|
2022
Q4 | $415K | Buy |
+1,431
| New | +$140K | ﹤0.01% | 3473 |
|
|
2020
Q1 | – | Sell |
-9,787
| Closed | -$892K | – | 3693 |
|
|
2019
Q4 | $892K | Sell |
9,787
-1,209
| -11% | -$117K | ﹤0.01% | 3105 |
|
|
2019
Q3 | $948K | Buy |
10,996
+4,560
| +71% | +$428K | ﹤0.01% | 3039 |
|
|
2019
Q2 | $675K | Sell |
6,436
-805
| -11% | -$86.2K | ﹤0.01% | 3223 |
|
|
2019
Q1 | $907K | Buy |
7,241
+85
| +1% | +$10.6K | ﹤0.01% | 3080 |
|
|
2018
Q4 | $807K | Buy |
7,156
+2,730
| +62% | +$423K | ﹤0.01% | 3022 |
|
|
2018
Q3 | $948K | Sell |
4,426
-3,302
| -43% | -$829K | ﹤0.01% | 3101 |
|
|
2018
Q2 | $2.16M | Sell |
7,728
-1,177
| -13% | -$207K | ﹤0.01% | 2703 |
|
|
2018
Q1 | $1.04M | Sell |
8,905
-11,363
| -56% | -$1.4M | ﹤0.01% | 2958 |
|
|
2017
Q4 | $1.86M | Buy |
+20,268
| New | +$1.16M | ﹤0.01% | 2684 |
|
|
2014
Q4 | – | Sell |
-11
| Closed | -$1K | – | 4110 |
|
|
2014
Q3 | $1K | Sell |
11
-3
| -21% | -$417 | ﹤0.01% | 5559 |
|
|
2014
Q2 | $2K | Buy |
14
+3
| +27% | +$438 | ﹤0.01% | 5216 |
|
|
2014
Q1 | $2K | Hold |
11
| – | – | ﹤0.01% | 5056 |
|
|
2013
Q4 | $2K | Sell |
11
-75
| -87% | -$13.7K | ﹤0.01% | 4883 |
|
|
2013
Q3 | $19K | Hold |
86
| – | – | ﹤0.01% | 4450 |
|
|
2013
Q2 | $15K | Buy |
+86
| New | +$22.4K | ﹤0.01% | 4482 |
|
Other funds holding MDGL
BBA
RI
ACA
PC
VPM
VCM
Ameriprise's MDGL Position: Q1 2026 in Review
Ameriprise increased its Madrigal Pharmaceuticals (MDGL) stake by 235% in Q1 2026, buying an estimated $32.9M and bringing the position to 98,181 shares worth $51.4M. The position accounts for 0.01% of the portfolio, ranked #857.
Ameriprise first reported a position in MDGL in Q2 2013 and has held it in 29 quarters since. 378 funds tracked by Wall St. Rank hold MDGL as of Q1 2026.
- Ameriprise held 98,181 shares of Madrigal Pharmaceuticals worth $51.4M as of Q1 2026.
- Ameriprise bought 68,894 Madrigal Pharmaceuticals shares in Q1 2026, an estimated $32.9M.
- Madrigal Pharmaceuticals made up 0.01% of Ameriprise's portfolio in Q1 2026, its #857 holding.
- Ameriprise first reported a position in Madrigal Pharmaceuticals in Q2 2013 and has held it in 29 quarters since.
- 378 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2026.
Based on Ameriprise's 13F filing for Q1 2026, filed 15 May 2026.